Korean J Med.
2015 Apr;88(4):459-463. 10.3904/kjm.2015.88.4.459.
Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma
- Affiliations
-
- 1Division of Hematology-Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea. sychong@cha.ac.kr
- KMID: 2269134
- DOI: http://doi.org/10.3904/kjm.2015.88.4.459
Abstract
- Bortezomib (Velcade(R)) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells. It has been hypothesized that the accumulation of damaged proteins in myocytes impairs cardiac function. Cardiotoxicity is a rare side effect of bortezomib treatment. We report a case of reversible systolic heart failure that probably occurred after bortezomib treatment in a patient with multiple myeloma. Patients being treated with bortezomib who have previously had cardiac comorbidities should undergo routine cardiac monitoring.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Acute Pancreatitis Caused by Bortezomib in a Patient with Multiple Myeloma
- A Case of Cutaneous Plasmacytoma Treated with Bortezomib and Radiotherapy
- Huge Cutaneous Involvement of Multiple Myeloma
- Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
- Bortezomib-induced Histiocytoid Sweet Syndrome
